PEAR THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.00% |
|
-.--% | -.--% |
| Mar. 22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
| Mar. 04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
ETFs positioned on Pear Therapeutics, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 18 M€ | +3.48% | - |
Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâs pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 142 | |
| +3.60% | 43.43B | |
| +47.81% | 41.69B | |
| +8.73% | 41.31B | |
| -10.92% | 27.14B | |
| +8.83% | 25.28B | |
| -24.36% | 18.47B | |
| +29.28% | 12.59B | |
| +1.14% | 12.33B | |
| +9.19% | 11.03B |
- Stock Market
- Equities
- PEARQ Stock
- Funds and ETFs Pear Therapeutics, Inc.
